Drug Discovery and Development Seminar Series

Description:

For More Information About This Series Contact:
Jamie Tammariello
Phone: 301-846-1064
E-Mail: jtammariello@ncifcrf.gov
Web:

Series Calendar:
1/21/2009	Charles Vinson, PhD	Arylstibonic Acids Inhibit B-ZIP DNA Binding: Where is the Specificity?
10/1/2008	Wolfgang Sadee, Dr.rer.nat	A Chemogenomics Approach to Discovery of Drug Targets, Novel Drugs, and Biomarkers in Cancer Chemotherapy
4/30/2008	Lyuba Varticovski, MD	Cancer Stem Cell: A Different Target?
11/28/2007	Lee Ellis, MD	Angiogenic Factors and Receptors in Colorectal Cancer: Challenging Existing Paradigms
5/23/2007	Garth Powis, D.Phil	Targeting the Stress Responses for Cancer Drug Discovery
5/2/2007	Stephen W. Fesik, PhD	CANCELLED--Bcl-2 Family Inhibitors for the Treatment of Cancer
4/4/2007	M. Celeste Simon, PhD	Hypoxia, HIFs and Stem Cells
2/7/2007	James Hsieh, MD, PhD	Proteolytic Signaling Pathways Led by Taspase 1
1/10/2007	Dr. Dean Tang	Hierarchical Organization of Human Prostate Cancer Cells: Regulation of Self-Renewal
5/31/2006	Charles D. Smith, PhD	Protein Palmitoylation as a New Target for Cancer Chemotherapy
4/26/2006	Yixian Zheng, Ph.D.	Spindle Morphogenesis and Chromosome Segregation
3/29/2006	James McAlpine, PhD	The Genomics of Secondary Metabolite Biosynthesis as a Platform for Drug Discovery
2/22/2006	John Condeelis, PhD	The Invasion Microenvironment of Mammary Tumors
1/25/2006	Dr. Pamela Silver	Modulation and Redesign of Nuclear Networks in Disease
9/28/2005	Bill J. Baker, PhD	Palmerolides: Macrolides from the Antarctic Tunicate Synoicum Adareanum that Target V-ATPase
3/23/2005	Richard J. Youle, PhD	The Role of Bc1-2 Family Members in Programmed Cell Death
2/9/2005	Ratna K. Vadlamudi, Ph.D.	The Role of ER Coactivator PELP1 in Tumorigenesis
1/26/2005	Lee Greenberger, Ph.D.	Novel Antimicrotubule Agents: From Mechanism of Action to Clinical Trials
1/12/2005	Hynda Kleinman, PhD	CANCELLED--Role of Laminins in Angiogenesis and Tumor Growth
12/8/2004	Steven K. Libutti, MD	New Strategies for Studying and Targeting Tumor-Associated Vasculature
10/13/2004	Roberto Pili	Histone Deacetylase Inhibitors: Therapeutic Strategies for Solid Tumore
5/26/2004	Dr. Louis Barrows	Neoamphimedine, a Topoisomerase Drug with a Twist
4/14/2004	Dr. William Hait	Targeting the Calcium/Calmodulin Signal Transduction Pathway for Anticancer Therapy
3/17/2004	Prof. James Gloer	The Chemistry of Fungal Antagonism and Defense: A Useful Guide to the Discovery of New Bioactive Natural Products
1/21/2004	W. Marston Linehan, MD	Genetic Basic of Kidney: Opportunity for Development of Disease-Specific Therapy
10/8/2003	Randall S. Johnson, Ph.D.	Hypoxia: The Genetics of a Physiological Response
9/24/2003	Dr. Marco Gottardis	Developing New Hormonal Therapies in Prostate Cancer
9/10/2003	Dr. John (Jay) Chiorini	Identification of PDGFR as a Receptor for AAV5 Transduction
4/16/2003	Heinz G. Floss, MD	Genetic Tools for the Biosynthetic Structure Modification of the Maytansinoid Antitumor Agents
3/19/2003	Dr. Donna Shewach	Gemcitabine: An Effective Agent for Enhancing Radiation Therapy and Enzyme/Prodrug Gene Therapy
3/5/2003	Dr. Steven Grant	Development of Rational Antileukemic Strategies Combining Novel Signal Transduction and Cell Cycle Inhibitors
2/25/2003	Dr. David Carlson	Automated Platform for SNP's to Measure CYP1A1 and IB1 SNP's in the 60 Cell Lines
2/19/2003	Dr. Marco Gottardis	Developing New Hormonal Therapies in Prostate Cancer
2/5/2003	Donald Small, MD, PhD, Johns Hopkins University School of Medicine	Targeting FLT3 as Specific Therapy for Leukemia
1/22/2003	Dr. Ivan N. Rich, HemoGenix LLC	HALO-A High Throughput, Multifunctional Assay Platform for Hemotoxicity during Drug Development and Basic and Clinical Hematopoietic Research
1/8/2003	Dr. Charles Tyson, SRI International	In vitro Systems to Predict Hepatobiliary Toxicity
12/11/2002	Karl Y. Hostetler, MD, University of California, San Diego	1-O-Hexadecyloxpropyl-Nucleoside Phosphonates: Possible Use in Cancer Therapy